Abstract:OBJECTIVE: The purpose of this study was to develop an ideal microsphere formulation of risperidone that would prolong the drug release for 3 months in vivo and avoid the need for co-administration of oral tablets.MATERIALS AND METHODS: Polycaprolactones (PCL) were used as polymers to prepare microspheres. The research included screening and optimizing of suitable commercial polymers of variable molecular weights: PCL-14000, PCL-45000, PCL-80000 or the blends of these polymers to prepare microspheres with zero-order drug-releasing properties without the lag phase. In the present study, the sustained release risperidone microspheres were prepared by o/w emulsion solvent evaporation technique and the yield was determined. Microspheres were evaluated for their drug content and in vitro drug release. Microspheres prepared using a blend of PCL-45000 and PCL-80000 at a ratio of 1:1 resulted in the release of the drug in a time frame of 90 days, demonstrated zero-order drug release without lag time and burst release. This formulation was considered optimized formulation. Optimized formulation was characterized for solid state of the drug using differential scanning calorimetry, surface morphology using scanning electron microscopy and in vivo drug release in rats.RESULTS: The surface of the optimized formulation was smooth, and the drug changed its physical form in the presence of blends of polymers and upon fabrication of microspheres. The optimized formulation also released the drug in vivo for a period of 90 days.CONCLUSIONS: From our study, it was concluded that these optimized microspheres showed great potential for a better depot preparation than the marketed Risperdal Consta™ and, therefore, could further improve patient compliance.

Accelerated Dissolution Method to Facilitate in Vitro Evaluation of Risperidone-Containing Microspheres

Study on pramipexole dihydrochloride sustained-release tablets

Accelerated Dissolution Testing for Controlled Release Microspheres Using the Flow-Through Dissolution Apparatus

Preparation and in vitro evaluation of risperidone loaded PLGA microspheres

Development of a novel 3-month drug releasing risperidone microspheres

Accelerated Release of Simvastatin Polylactic Acid Microspheres in Vitro

Formation Mechanism and in Vitro Evaluation of Risperidone-Containing PLGA Microspheres Fabricated by Ultrafine Particle Processing System.

Pharmacokinetics and Pharmacodynamics Evaluation on Risperidone-Containing Microsphere Fabricated by Ultra-Fine Particle Processing System

Preparation and in Vitro Release of Glipizide Loaded Controlled Release Microspheres

Preparation of uniform microcapsules with silicone oil as continuous phase in a micro-dispersion process.

Risperidone-loaded Long-Acting Injectable Microspheres Prepared by Ultra-Fine Particle Processing System

Effects of Formulation Parameters on Encapsulation Efficiency and Release Behavior of Risperidone Poly(d,l-Lactide-co-glycolide) Microsphere.

Biodegradable Poly(d, L-lactide-co-glycolide) (PLGA) Microspheres for Sustained Release of Risperidone: Zero-order Release Formulation.

Development and Validation of Dissolution Testings in Acidic Media for Rabeprazole Sodium Delayed-Release Capsules.

Advanced Studies in the Preparation Techniques of Sustained-release Microsphere

Preliminary Development of Solid Dispersion for an Insoluble Compound ZL006 by Miniaturized Hot Melt Extrusion

Modulation of Release Rates of Risperidone Loaded Microspheres by Mg(OH)_2

Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo

Novel Preparation Method for Sustained-Release Plga Microspheres Using Water-In-Oil-In-Hydrophilic-Oil-In-Water Emulsion

Study on Preparation and in vitro Characterization of Tranilast Poly(D,L-lactide) Microspheres by a Modified Solvent Evaporation/Extraction Method

Microscope-enabled disc dissolution system: Concordance between drug and polymer dissolution from an amorphous solid dispersion disc and visual disc degradation